sutthirat sutthisumdang
Bernstein modernized beam treatments (Nasdaq:beam) to outperform the market, citing upcoming data on the company’s drug candidate for treating alpha-1 antitrypsin deficiency, or AATD.
The investment firm said it believes the data will be positive, adding: “Good data can be valuable
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1362707165/image_1362707165.jpg?io=getty-c-w750
Source link